We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

98 hedge funds and large institutions have $67.8M invested in Aclaris Therapeutics in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 39 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $62.4M → $67.8M (+$5.39M)

7.17% less ownership

Funds ownership: 83.94% → 76.77% (-7.2%)

8% less funds holding

Funds holding: 107 → 98 (-9)

19% less call options, than puts

Call options by funds: $76K | Put options by funds: $94K

31% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 39

33% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 27

Holders
98
Holders Change
-9
Holders Change %
-8.41%
% of All Funds
1.41%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
18
Increased
27
Reduced
39
Closed
27
Calls
$76K
Puts
$94K
Net Calls
-$18K
Net Calls Change
-$43K

Top Buyers

1
BCM
BML Capital Management
Indiana
+$10.4M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.6M
3
AQR Capital Management
AQR Capital Management
Connecticut
+$730K
4
PAI
Palo Alto Investors
California
+$680K
5
AI
Acuitas Investments
Washington
+$551K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$5.32M
2
VCIM
Velan Capital Investment Management
Georgia
-$1.85M
3
TCM
Tang Capital Management
California
-$1.84M
4
Morgan Stanley
Morgan Stanley
New York
-$1.74M
5
GCP
GSA Capital Partners
United Kingdom
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
1
BML Capital Management
Indiana
$11.7M +$10.4M +8,742,827 +1,339%
BlackRock
2
BlackRock
New York
$6.45M -$839K -703,725 -12%
Vanguard Group
3
Vanguard Group
Pennsylvania
$6.11M +$247K +207,418 +4%
D.E. Shaw & Co
4
D.E. Shaw & Co
New York
$4.07M +$1.6M +1,343,972 +69%
Millennium Management
5
Millennium Management
New York
$4.06M -$245K -205,869 -6%
BCLSI
6
Bain Capital Life Sciences Investors
Massachusetts
$3.72M -$596K -500,000 -14%
RSCM
7
Rock Springs Capital Management
Maryland
$3.41M -$292K -245,000 -8%
Acadian Asset Management
8
Acadian Asset Management
Massachusetts
$2.65M -$258K -216,040 -9%
Renaissance Technologies
9
Renaissance Technologies
New York
$2.08M -$87.1K -73,032 -4%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$1.94M +$205K +171,506 +12%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$1.8M +$35.9K +30,100 +2%
State Street
12
State Street
Massachusetts
$1.66M -$59.6K -50,000 -4%
Two Sigma Investments
13
Two Sigma Investments
New York
$1.65M -$160K -133,845 -9%
Qube Research & Technologies (QRT)
14
Qube Research & Technologies (QRT)
United Kingdom
$1.5M -$558K -467,645 -28%
Deutsche Bank
15
Deutsche Bank
Germany
$1.19M +$27.4K +22,975 +2%
Citadel Advisors
16
Citadel Advisors
Florida
$1.15M -$5.32M -4,458,786 -83%
SB
17
Samsara BioCapital
California
$863K – – –
GCP
18
GSA Capital Partners
United Kingdom
$842K -$1.08M -908,858 -57%
Fidelity Investments
19
Fidelity Investments
Massachusetts
$833K +$1.33K +1,114 +0.2%
AQR Capital Management
20
AQR Capital Management
Connecticut
$759K +$730K +612,205 New
PAI
21
Palo Alto Investors
California
$707K +$680K +569,832 New
Northern Trust
22
Northern Trust
Illinois
$697K -$116K -97,413 -15%
Morgan Stanley
23
Morgan Stanley
New York
$610K -$1.74M -1,460,092 -75%
AI
24
Acuitas Investments
Washington
$572K +$551K +461,663 New
ACM
25
Aisling Capital Management
New York
$539K – – –
1
2 3 4 5

ACRS Hedge Fund Activity: Q1 2024 in Review

98 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2024, worth a combined $67.8M — up 8.6% from $62.4M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of ACRS and 18 opened new positions — a net loss of 9 holders — while 39 trimmed existing stakes and 27 added.

The largest buyer was BML Capital Management, adding an estimated $10.4M. The largest seller was Citadel Advisors, cutting an estimated $5.32M.

  • 98 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2024, down from 107 in Q4 2023.
  • Funds reported $67.8M of Aclaris Therapeutics stock for Q1 2024, up 8.6% quarter-over-quarter.
  • 18 funds opened new Aclaris Therapeutics positions in Q1 2024 and 27 closed out, a net change of -9 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2024 was BML Capital Management, an estimated $10.4M added.
  • The largest Aclaris Therapeutics seller in Q1 2024 was Citadel Advisors, an estimated $5.32M sold.

Based on aggregated 13F filings for Q1 2024.